AbbVie Inc.

AbbVie sells primarily to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers, with some aesthetic products also sold directly to physicians and licensed health care providers. In the United States, a small number of large wholesale distributors account for most pharmaceutical product sales, which makes channel execution and inventory management important. Outside the United States, the company relies more heavily on distributors and centralized payer systems, so reimbursement access and formulary placement are critical to demand. End customers are ultimately patients and prescribers, but purchasing decisions are influenced by physicians, managed care organizations, hospitals, and government payers. AbbVie also supports patients through support programs tied closely to its branded therapies.

AbbVie's strategy is to diversify revenue across multiple long-duration growth drivers while continuing to invest in its pipeline and on-market products. The company is prioritizing commercial execution for key brands such as Skyrizi, Rinvoq, Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev, Venclexta, Elahere, Botox Cosmetic, and Juvederm. It is also expanding into new growth areas, including obesity, while pursuing late-stage clinical milestones and indication expansions in core therapeutic areas. Cash generation, dividend growth, debt repayment, and maintaining investment-grade credit quality are central to the capital allocation framework. External innovation, acquisitions, and licensing remain important to supplement internal R&D and extend the product portfolio.